Impact of EMpagliflozin on Cardiac Function and Biomarkers of Heart Failure in Patients With Acute MYocardial Infarction

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2017
This study is planned to investigate the impact of Empagliflozin on biomarkers of heart failure in patients with myocardial infarction with and without type 2 diabetes mellitus within 6 months after the event.
Epistemonikos ID: b3531bf1532faa5eff9ad76f8549db32bb0fec5b
First added on: May 20, 2024